Cenduit To Launch Quantum Interactive™ Solution At DIA 2017

Celebrating its 10-year anniversary, Cenduit LLC, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions and expertise as the largest interactive response technology (IRT) specialist in the world at DIA 2017, June 19-21 in Chicago. Cenduit’s new CEO Sam Osman will be present at the show, where the company will be launching its newest rapid study build software, Quantum Interactive™.

A technology-based innovation unlike any other in the market, Quantum Interactive increases IRT quality by creating a functioning prototype of an initial study build within minutes. The tool provides a user-friendly interface to guide the study building process for faster requirements discovery and is highly configurable, regardless of study design.

“The ability to increase agility and reduce timelines is critical for success in clinical studies,” said Kim Lanza-Russo, director of product management, Cenduit. “Quantum Interactive gives sponsors the ability to bypass delays, such as lengthy requirements periods. With this tool, a fully functioning system can be ready in minutes with a higher quality end result.”

Attendees are invited to stop by Cenduit booth #1520 for a demonstration of Quantum Interactive and learn how the company’s IRT solutions can help sponsors increase efficiencies and quality delivery, saving study teams time and resources.

About Cenduit
Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Cenduit and has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For more information, visit www.cenduit.com.